^
Association details:
| Biomarker: | BRAF V600K |
|---|---|
| Cancer: | Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) + Cotellic (cobimetinib) (MEK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
Published date:
11/23/2022
Excerpt:
This investigator-initiated, phase I trial evaluated pembrolizumab, vemurafenib, and cobimetinib in patients with untreated, BRAFV600E/K mutant advanced melanoma.....Triple therapy with vemurafenib, cobimetinib and pembrolizumab is associated with high response rates but significant adverse events, leading to early study closure.
DOI:
10.3389/fonc.2022.1022496
Trial ID:
